Three cases of nivolumab therapy-failed advanced melanoma successfully controlled by ipilimumab with intensity-modulated radiotherapy

Ryo Amagai, Taku Fujimura, Yumi Kambayashi, Yota Sato, Kayo Tanita, Akira Hashimoto, Setsuya Aiba

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

Anti-programmed death 1 antibody monotherapy is a first-line and widely used immunotherapy for the treatment of advanced melanoma. However, its efficacy rate is lower in the Japanese population compared with the Caucasian population. Ipilimumab is another immune checkpoint inhibitor (ICI) that activates and increases T cells, which suppress the function of regulatory T cells. Previous reports have suggested that ipilimumab is useful for treating advanced melanoma, particularly in combination with radiation therapy. In this report, we described three cases of nivolumab-resistant melanoma successfully controlled by ipilimumab with intensity-modulated radiotherapy, which may enhance the therapeutic effects of the sequential administration of ICI.

Original languageEnglish
Pages (from-to)449-452
Number of pages4
JournalJournal of Dermatology
Volume46
Issue number5
DOIs
Publication statusPublished - 2019 May

Keywords

  • adverse events
  • intensity-modulated radiotherapy
  • ipilimumab
  • low-dose radiation therapy
  • nivolumab

ASJC Scopus subject areas

  • Dermatology

Fingerprint

Dive into the research topics of 'Three cases of nivolumab therapy-failed advanced melanoma successfully controlled by ipilimumab with intensity-modulated radiotherapy'. Together they form a unique fingerprint.

Cite this